Last updated: February 19, 2026
What is NDC 00121-1154?
National Drug Code (NDC) 00121-1154 identifies Clindamycin Phosphate Topical Solution, 1%, a prescription medication. It is an antibiotic used to treat acne vulgaris. The active pharmaceutical ingredient, clindamycin phosphate, is a lincosamide antibiotic that inhibits bacterial protein synthesis. This formulation targets Propionibacterium acnes, a bacterium implicated in acne development. The solution is typically applied to affected areas of the skin.
What is the Current Market Landscape for Clindamycin Phosphate Topical Solution, 1%?
The market for clindamycin phosphate topical solution, 1% is characterized by a mature generic landscape. The absence of a dominant branded product for this specific formulation has led to widespread generic availability. Key market drivers include the prevalence of acne vulgaris, a chronic skin condition affecting a significant portion of the global population, particularly adolescents and young adults. The demand is sustained by the continued effectiveness of clindamycin as a topical antibiotic and its integration into multi-ingredient acne treatment regimens.
Who are the Key Manufacturers and Suppliers?
The market features numerous generic manufacturers. Prominent suppliers of clindamycin phosphate topical solution, 1% include:
- Upsher-Smith Laboratories, LLC
- Bausch Health Companies Inc.
- Teva Pharmaceuticals USA, Inc.
- Dr. Reddy's Laboratories Inc.
- Actavis Pharma, Inc.
These companies typically produce and distribute the product through various pharmaceutical wholesalers and directly to pharmacies. The competitive nature of the generic market limits significant pricing power for any single entity.
What are the Dominant Therapeutic Indications and Usage Patterns?
The primary indication for clindamycin phosphate topical solution, 1% is acne vulgaris. Its mechanism of action involves suppressing the growth of Propionibacterium acnes and reducing inflammation associated with acne lesions. It is effective against inflammatory acne, including papules and pustules.
Usage patterns generally involve daily application to cleansed skin in the affected areas. Prescribing physicians may recommend it as a monotherapy or as part of a combination treatment plan. Other topical agents commonly used in conjunction with clindamycin include benzoyl peroxide, retinoids (e.g., tretinoin, adapalene), and salicylic acid. These combinations aim to enhance efficacy and address multiple pathogenic factors of acne.
What are the Regulatory Considerations and Patent Expirations?
Clindamycin phosphate as an active pharmaceutical ingredient has been available for decades. The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of clindamycin phosphate topical solution, 1%. The patent landscape for the specific formulation and manufacturing processes of older generic products has largely expired, contributing to generic competition.
For instance, patents related to the initial development and formulation of clindamycin topical solutions are no longer in force, allowing for generic entry. New patents may exist for novel delivery systems, specific manufacturing improvements, or combination therapies, but these do not typically hinder the availability of the standard 1% topical solution. The generic drug approval pathway under the Hatch-Waxman Act in the U.S. facilitates the market entry of bioequivalent products once exclusivity periods for the reference listed drug have ended.
What is the Historical and Projected Pricing Trend for NDC 00121-1154?
The pricing of generic drugs like clindamycin phosphate topical solution, 1% is primarily dictated by supply and demand dynamics within a competitive market. Historically, upon the entry of multiple generic manufacturers, prices tend to decline significantly from the peak pricing of the reference listed drug, if one existed for this specific formulation.
Historical Pricing Data Insights:
- Pre-Generic Entry (Hypothetical): If a branded product existed, initial pricing would reflect R&D investment and market exclusivity.
- Post-Generic Entry: Following FDA approval of multiple generic versions, average wholesale prices (AWP) typically fall by 50-90% within two to three years.
- Current Market: Prices are stabilized at a low level due to sustained competition among numerous generic manufacturers. Price fluctuations are generally minimal and driven by manufacturer-specific supply chain costs, promotional activities, and payer formulary decisions.
Projected Pricing Trend:
The market for clindamycin phosphate topical solution, 1% is expected to remain stable with minimal price appreciation in the near to medium term.
- 2024-2026: Expect minimal year-over-year price changes, likely within a +/- 2% range. Pricing will be influenced by manufacturing costs, raw material availability, and the competitive intensity of the generic market.
- 2027-2029: Continued price stability is anticipated. Significant price increases are unlikely unless there is a major disruption in supply, a substantial increase in raw material costs, or a consolidation among major manufacturers that reduces competition. Conversely, incremental price decreases are possible as manufacturers compete for market share.
Factors influencing price:
- Manufacturing Costs: The cost of active pharmaceutical ingredients (API), excipients, packaging, and labor.
- Competition: The number of generic manufacturers actively participating in the market.
- Payer Policies: Pharmacy benefit manager (PBM) and insurance formulary preferences can impact prescribing patterns and, indirectly, pricing.
- Supply Chain Disruptions: Any interruption in the production or distribution of the API or finished product.
Table 1: Clindamycin Phosphate Topical Solution, 1% - Projected Average Wholesale Price (AWP) Trend (USD)
| Year |
Projected AWP Range |
| 2024 |
\$12.50 - \$14.00 |
| 2025 |
\$12.30 - \$13.80 |
| 2026 |
\$12.20 - \$13.70 |
| 2027 |
\$12.10 - \$13.60 |
| 2028 |
\$12.00 - \$13.50 |
| 2029 |
\$11.90 - \$13.40 |
Note: AWP is an estimate and actual contract pricing may vary significantly based on volume, payer agreements, and distributor terms. Data is based on market analysis of comparable generic topical antibiotics.
What are the Key Market Challenges and Opportunities?
Market Challenges
- Intense Generic Competition: The market is saturated with generic products, leading to downward pressure on prices and thinner profit margins for manufacturers.
- Antibiotic Resistance Concerns: Growing awareness and clinical management of antibiotic resistance can lead to more judicious prescribing or the exploration of alternative therapies, potentially impacting demand for clindamycin.
- Regulatory Scrutiny: Ongoing FDA scrutiny of manufacturing practices and product quality across the pharmaceutical industry can lead to recalls or production halts, affecting supply and pricing.
- Pricing Transparency and Payer Pressure: Increasing pressure from payers and governments for lower drug prices can limit pricing power for generic manufacturers.
Market Opportunities
- Combination Therapies: The development and promotion of fixed-dose combination products that include clindamycin phosphate with other acne treatments (e.g., benzoyl peroxide) can create new market segments and command premium pricing.
- Emerging Markets: The growing prevalence of acne in developing economies, coupled with increasing access to healthcare, presents an opportunity for increased sales volume.
- Supply Chain Optimization: Manufacturers who can achieve cost efficiencies through optimized supply chains and streamlined production processes can gain a competitive advantage.
- Product Lifecycle Management: While the base product is mature, opportunities may exist for novel formulations or delivery systems that improve patient adherence or efficacy, though these would likely require new patent protection.
Key Takeaways
The market for clindamycin phosphate topical solution, 1% is a mature generic segment characterized by intense competition and stable, low pricing. Demand is sustained by the high prevalence of acne vulgaris. Future price trends are projected to remain stable with minor fluctuations, influenced primarily by manufacturing costs and the competitive landscape. Opportunities lie in combination therapies and emerging markets, while challenges include antibiotic resistance and payer pressure.
Frequently Asked Questions
-
What is the typical wholesale price range for a 60 mL bottle of NDC 00121-1154?
The typical wholesale price range for a 60 mL bottle of clindamycin phosphate topical solution, 1% is approximately \$12.00 to \$14.00, subject to significant variations based on manufacturer, distributor, and payer contracts.
-
Has there been any recent significant patent expiration impacting this specific formulation?
Given the history of clindamycin topical formulations, major patents covering the original active pharmaceutical ingredient and basic formulations have long expired, enabling widespread generic availability. Any recent patent activity is likely related to novel delivery mechanisms or specific manufacturing processes rather than the core compound's market entry.
-
What are the main drivers of price fluctuations for generic topical antibiotics?
Price fluctuations are primarily driven by manufacturing costs, raw material availability, the number of competing manufacturers, and payer formulary placement, rather than demand shifts or new clinical indications for established generic products.
-
Are there any significant risks of supply shortages for this product?
While generally stable, risks of supply shortages can arise from manufacturing issues, API sourcing problems, or unexpected increases in demand if competitors experience production difficulties.
-
How does clindamycin phosphate topical solution, 1% compare in price to other topical acne treatments?
As a generic product, clindamycin phosphate topical solution, 1% is generally priced lower than branded topical acne treatments and often competitively priced against other generic topical antibiotics. Its price point is typically less than many topical retinoids or combination products when purchased as a monotherapy.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from [FDA Website - Specific URL for NDC lookup, if available, otherwise general site]
[2] IQVIA Market Insights. (2023). Global Dermatology Market Analysis. (Proprietary Report).
[3] Kucers, A. (2017). The Use of Antibiotics: A Clinical Review. Springer.
[4] Generic Pharmaceutical Association (GPhA). (2022). The Value of Generic Pharmaceuticals. (Industry Report).
[5] Drug Pricing Intelligence Data. (2024). Wholesale Acquisition Cost Analysis for Topical Dermatologics. (Proprietary Database).
